Terremoto Biosciences

Terremoto creates highly targeted, small molecule AKT1-inhibitors for advanced cancer and rare genetic vascular disorders.

Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series C
Initial Investment Year
2026
Terremoto Bio Hover Image